English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The International League of Associations for Rheumatology (ILAR) has been meeting with the World Health Organization (WHO) on a regular basis to discuss issues of mutual interest. Over the last few years these meetings have focused on the development of outcome measures in the rheumatic diseases, principally driven through OMERACT (Outcome Measures for Arthritis Clinical Trials). OMERACT has now held five meetings addressing a number of important areas in rheumatology, including clinical and imaging outcome measures, health economics and drug safety. The advantage of the WHOuILAR Task Force Meeting has been to ratify these measures and allow them to be promulgated widely around the world. This paper summarizes discussions which took place at the Sixth Joint WHOuILAR Task Force Meeting on Rheumatic Diseases which was held in Geneva on 16 January 2000. This meeting reviewed a number of outcome measures for rheumatic diseases that had been developed over the past few years under the aegis of OMERACT. The WHOuILAR meeting formally endorsed these outcome measures and acknowledged them as the gold standard for outcome measures in these conditions. At the same meeting, a series of criteria for the classification of rheumatic diseases was also reviewed. These criteria have also been established through discussion by a number of different organizations, including ILAR, the American College of Rheumatology and EULAR (the European League of Associations for Rheumatology). These classification criteria have been put together by experts and have been adopted widely throughout the world. The meeting recommended that WHOuILAR adopt these wellrecognized classification criteria and encourage their use in clinical and epidemiological studies. It should be noted that classification criteria should not be used as diagnostic criteria but for the purposes of classifying patients in studies. An understanding of this concept will help in the interpretation of many clinical studies.

british journal of rheumatology

Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups